Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2005

01-12-2005 | Original Article

Timing of Critical Genetic Changes in Human Breast Disease

Authors: Rachel E. Ellsworth, PhD, Darrell L. Ellsworth, PhD, Brenda Deyarmin, HT(ASCP), Laurel R. Hoffman, BS, Brad Love, PhD, Jeffrey A. Hooke, MD, Craig D. Shriver, MD

Published in: Annals of Surgical Oncology | Issue 12/2005

Login to get access

Abstract

Background

Breast cancer development has been characterized as a nonobligatory sequence of histological changes from normal epithelium through invasive malignancy. Although genetic alterations are thought to accumulate stochastically during tumorigenesis, little is known about the timing of critical mutations. This study examined allelic imbalance (AI) in tissue samples representing a continuum of breast cancer development to examine the evolution of genomic instability.

Methods

Laser-microdissected DNA samples were collected from histologically normal breast specimens (n = 25), atypical ductal hyperplasia (ADH, n = 16), ductal carcinoma-in-situ (DCIS, n = 37), and stage I to III invasive carcinomas (n = 72). Fifty-two microsatellite markers representing 26 chromosomal regions commonly deleted in breast cancer were used to assess patterns of AI.

Results

AI frequencies were <5% in histologically normal and ADH specimens, 20% in DCIS lesions, and approximately 25% in invasive tumors. Mann-Whitney tests showed (1) that levels of AI in ADH samples did not differ significantly from those in histologically normal tissues and (2) that AI frequencies in DCIS lesions were not significantly different from those in invasive carcinomas. ADH and DCIS samples, however, differed significantly (P < .0001).

Conclusions

DCIS lesions contain levels of genomic instability that are characteristic of advanced invasive tumors, and this suggests that the biology of a developing carcinoma may already be predetermined by the in situ stage. Observations that levels of AI in ADH lesions are similar to those in disease-free tissues provide a genomic rationale for why prevention strategies at the ADH level are successful and why cases with ADH involving surgical margins do not require further resection.
Literature
1.
go back to reference Couch FJ, Weber BL. Breast cancer. In: Vogelstein B, Kinzler K, eds. The Genetic Basis of Human Cancer. New York: McGraw-Hill, 2002:549–81 Couch FJ, Weber BL. Breast cancer. In: Vogelstein B, Kinzler K, eds. The Genetic Basis of Human Cancer. New York: McGraw-Hill, 2002:549–81
2.
go back to reference Devilee P, Cornelisse CJ. Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1994;1198:113–30PubMed Devilee P, Cornelisse CJ. Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1994;1198:113–30PubMed
3.
go back to reference O’Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697–703PubMed O’Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697–703PubMed
4.
go back to reference Euhus DM, Cler L, Shivapurkar N, et al. Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. J Natl Cancer Inst 2002;94:858–60PubMed Euhus DM, Cler L, Shivapurkar N, et al. Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. J Natl Cancer Inst 2002;94:858–60PubMed
5.
go back to reference Kaneko M, Arihiro K, Takeshima Y, Fujii S, Inai K. Loss of heterozygosity and microsatellite instability in epithelial hyperplasia of the breast. J Exp Ther Oncol 2002;2:9–18CrossRefPubMed Kaneko M, Arihiro K, Takeshima Y, Fujii S, Inai K. Loss of heterozygosity and microsatellite instability in epithelial hyperplasia of the breast. J Exp Ther Oncol 2002;2:9–18CrossRefPubMed
6.
go back to reference American Joint Committee on Cancer. AJCC Cancer Staging Manual. New York: Springer, 2002 American Joint Committee on Cancer. AJCC Cancer Staging Manual. New York: Springer, 2002
7.
go back to reference The Consensus Conference Committee. Consensus conference on the classification of ductal carcinoma in situ. Hum Pathol 1997;28:1221–5 The Consensus Conference Committee. Consensus conference on the classification of ductal carcinoma in situ. Hum Pathol 1997;28:1221–5
8.
go back to reference Ellsworth DL, Shriver CD, Ellsworth RE, Deyarmin B, Somiari RI. Laser capture microdissection of paraffin-embedded tissues. Biotechniques 2003;34:42–6PubMed Ellsworth DL, Shriver CD, Ellsworth RE, Deyarmin B, Somiari RI. Laser capture microdissection of paraffin-embedded tissues. Biotechniques 2003;34:42–6PubMed
9.
go back to reference Ellsworth RE, Ellsworth DL, Lubert SM, Hooke J, Somiari RI, Shriver CD. High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:915–9PubMed Ellsworth RE, Ellsworth DL, Lubert SM, Hooke J, Somiari RI, Shriver CD. High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:915–9PubMed
10.
go back to reference Medintz IL, Lee C-CR, Wong WW, Pirkola K, Sidransky D, Mathies RA. Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res 2000;10:1211–8CrossRefPubMed Medintz IL, Lee C-CR, Wong WW, Pirkola K, Sidransky D, Mathies RA. Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res 2000;10:1211–8CrossRefPubMed
11.
go back to reference Ellsworth DL, Ellsworth RE, Love B, et al. Outer breast quadrants demonstrate increased levels of genomic instability. Ann Surg Oncol 2004;11:861–8CrossRefPubMed Ellsworth DL, Ellsworth RE, Love B, et al. Outer breast quadrants demonstrate increased levels of genomic instability. Ann Surg Oncol 2004;11:861–8CrossRefPubMed
12.
go back to reference Janssen EA, Baak JP, Guervos MA, van Diest PJ, Jiwa M, Hermsen MA. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 2003;201:555–61CrossRefPubMed Janssen EA, Baak JP, Guervos MA, van Diest PJ, Jiwa M, Hermsen MA. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 2003;201:555–61CrossRefPubMed
13.
go back to reference Leighton X, Srikantan V, Pollard HB, Sukumar S, Srivastava M. Significant allelic loss of ANX7 region (10q21) in hormone receptor negative breast carcinomas. Cancer Lett 2004;210:239–44CrossRefPubMed Leighton X, Srikantan V, Pollard HB, Sukumar S, Srivastava M. Significant allelic loss of ANX7 region (10q21) in hormone receptor negative breast carcinomas. Cancer Lett 2004;210:239–44CrossRefPubMed
14.
go back to reference Schlechter BL, Yang Q, Larson PS, et al. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol 2004;22:1830–8CrossRefPubMed Schlechter BL, Yang Q, Larson PS, et al. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol 2004;22:1830–8CrossRefPubMed
15.
go back to reference Lichy JH, Zavar M, Tsai MM, O’Leary TJ, Taubenberger JK. Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast. Am J Pathol 1998;153:271–8PubMed Lichy JH, Zavar M, Tsai MM, O’Leary TJ, Taubenberger JK. Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast. Am J Pathol 1998;153:271–8PubMed
16.
go back to reference Radford DM, Phillips NJ, Fair KL, Ritter JH, Holt M, Donis-Keller H. Allelic loss and the progression of breast cancer. Cancer Res 1995;55:5180–3PubMed Radford DM, Phillips NJ, Fair KL, Ritter JH, Holt M, Donis-Keller H. Allelic loss and the progression of breast cancer. Cancer Res 1995;55:5180–3PubMed
17.
go back to reference Watatani M, Inui H, Nagayama K, et al. Identification of high-risk breast cancer patients from genetic changes of their tumors. Surg Today 2000;30:516–22CrossRefPubMed Watatani M, Inui H, Nagayama K, et al. Identification of high-risk breast cancer patients from genetic changes of their tumors. Surg Today 2000;30:516–22CrossRefPubMed
18.
go back to reference Champeme MH, Bieche I, Beuzelin M, Lidereau R. Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis. Genes Chromosomes Cancer 1995;12:304–6PubMed Champeme MH, Bieche I, Beuzelin M, Lidereau R. Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis. Genes Chromosomes Cancer 1995;12:304–6PubMed
19.
go back to reference Ingvarsson S. Molecular genetics of breast cancer progression. Cancer Biol 1999;9:277–88 Ingvarsson S. Molecular genetics of breast cancer progression. Cancer Biol 1999;9:277–88
20.
go back to reference Radford DM, Fair KL, Phillips TJ, et al. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 1995;55:3399–405PubMed Radford DM, Fair KL, Phillips TJ, et al. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 1995;55:3399–405PubMed
21.
go back to reference Yaremko ML, Recant WM, Westbrook CA. Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer 1995;13:186–91PubMed Yaremko ML, Recant WM, Westbrook CA. Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer 1995;13:186–91PubMed
22.
go back to reference Allred DC, Mohsin SK, Fuqua SAW. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001;8:47–61CrossRefPubMed Allred DC, Mohsin SK, Fuqua SAW. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001;8:47–61CrossRefPubMed
23.
go back to reference Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974–9CrossRefPubMed Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974–9CrossRefPubMed
24.
go back to reference Chitemerere M, Andersen TI, Holm R, Karlsen F, Borresen AL, Nesland JM. P53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Br Cancer Res Treat 1996;41:103–9 Chitemerere M, Andersen TI, Holm R, Karlsen F, Borresen AL, Nesland JM. P53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Br Cancer Res Treat 1996;41:103–9
25.
go back to reference Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88CrossRefPubMed
26.
go back to reference Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993–2000PubMed Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993–2000PubMed
27.
go back to reference Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83:1688–95CrossRefPubMed Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83:1688–95CrossRefPubMed
Metadata
Title
Timing of Critical Genetic Changes in Human Breast Disease
Authors
Rachel E. Ellsworth, PhD
Darrell L. Ellsworth, PhD
Brenda Deyarmin, HT(ASCP)
Laurel R. Hoffman, BS
Brad Love, PhD
Jeffrey A. Hooke, MD
Craig D. Shriver, MD
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2005.03.522

Other articles of this Issue 12/2005

Annals of Surgical Oncology 12/2005 Go to the issue